VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PSNL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PSNLPersonalis, Inc.
$14.98$1.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
PSNL logo

Personalis, Inc.

PSNL
NASDAQ · Diagnostics & Lab Testing
$14.98
At close - Nov 18, 4:00 PM EST - USD
Market Cap$1.6B
P/E-13.5x
52W High$18.89
Volume1.47M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Clinical Volume Surge Masks Persistent Cash Burn

Personalis is navigating a pivotal inflection, with Q2 2026 clinical volume surging 199% YoY and revenue up 33% sequentially to $22.4M, yet the company remains deeply unprofitable, posting a -150.2% operating margin and a -$31.7M net loss.

GrowthMixed
ProfitabilityWeak
ValuationReview
TechnicalsMixed
Explore valuation models
MARKET ACTION

PSNL price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-140% Peers

P/E is 140% below peer median

03

Market leadership

RS 94 · Leader

High momentum (Outperforming 94% of market)

04

Mixed Trend

Mixed

Price < 50DMA but > 200DMA

Next CatalystEstimated earnings · Feb 4

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
PSNL+90.83%
S&P 500 (^GSPC)+6.88%
1-Year Return
PSNL+96.59%
S&P 500 (^GSPC)+10.62%
3-Year Return
PSNL+1009.63%
S&P 500 (^GSPC)+7.20%
5-Year Return
PSNL-2.54%
S&P 500 (^GSPC)+66.30%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-13.5x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-13.5x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.40-90.7%
Base (Fair)$11.85-24.6%
Bull$1.73-88.5%
$1.40 Bear$11.85 Base$1.73 Bull
Current Market Price: $14.98
Trades at a 26.4% premium to Base DCF ($11.85)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$70M-17.7% YoY
Net income FY25
-$81M+0.0% YoY
Free cash flow FY25
-$79M-69.9% YoY
Operating margin FY25
-126.4%-45.8 pts YoY
ROIC (FY25)-39.7%
Avg ROIC 5Y-37.8%
ROE (TTM)-49.5%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate9/12 (75%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 4, 2026
-$0.32-21.5%
vs -$0.26
$26M+18.8%
vs $22M
Q3 2026
Aug 4, 2026
-$0.30-13.9%
vs -$0.26
$22M+34.0%
vs $17M
Q2 2026
May 7, 2026
-$0.29-26.1%
vs -$0.23
$15M+6.8%
vs $14M
Q1 2026
Feb 26, 2026
-$0.26+16.1%
vs -$0.31
$17M+1.7%
vs $17M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
24/7 Wall Street·Oct 27, 2026
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings

Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.

GuruFocus·Oct 21, 2026
PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced -- Investors are Alerted to Contact BFA Law

Leading securities law firm [url="]Bleichmar Fonti and Auld LLP[/url] announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ

Business Wire·Oct 21, 2026
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3.

Business Wire·Oct 20, 2026
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, includi.

Filtered for Personalis, Inc.More Headlines
04

Compare before deciding

Benchmark PSNL against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Personalis, Inc. (PSNL)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PSNL logoPSNLPersonalis, Inc.Current
$14.98$1.6B-13.46-17.69%-147.74%-49.52%—
NTRA logoNTRANatera, Inc.
$289.50$41.46B-253.2135.9%-5.66%-9.18%—
GH logoGHGuardant Health, Inc.
$145.14$19.25B-40.2232.88%-37.93%——
TWST logoTWSTTwist Bioscience Corporation
$116.35$7.25B-55.9522%-28.34%-23.2%—
ILMN logoILMNIllumina, Inc.
$210.01$31.77B36.14-0.78%19.72%31.45%—
PACB logoPACBPacific Biosciences of California, Inc.
$1.83$568.4M-4.343.89%-81.31%-2618.51%—

Compare PSNL vs Peers

Personalis, Inc. (PSNL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NTRA

Most directly comparable listed peer for PSNL.

Scale Benchmark

vs TMO

Larger-name benchmark to compare PSNL against a more recognizable public peer.

Peer Set

Compare Top 5

vs NTRA, GH, TWST, ILMN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

PSNL SEC Filings & Documents

Personalis, Inc. (PSNL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 4, 2026·SEC

Material company update

Jul 20, 2026·SEC

Material company update

Jul 20, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 4, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 4, 2025·SEC

Get notified when PSNL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PSNL Frequently Asked Questions

Personalis, Inc. (PSNL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Personalis, Inc.'s revenue?

Personalis, Inc. (PSNL) reported $80.8M in revenue over the trailing twelve months. Revenue was $69.6M in fiscal year 2025. That is 641% more than the $9.4M of fiscal year 2017.

How fast is Personalis, Inc. growing?

Personalis, Inc. (PSNL) grew revenue by 16.9% over the trailing twelve months, compared with the twelve months before.

Is PSNL profitable?

No. Personalis, Inc. (PSNL) reported a net loss of $119.3M over the trailing twelve months.

Dividend & Returns
What is PSNL's return on equity?

Personalis, Inc. (PSNL) had a return on equity (ROE) of -49.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Personalis, Inc.'s free cash flow?

Personalis, Inc. (PSNL) had negative free cash flow of $107.7M over the trailing twelve months.

What if you invested $1,000 in PSNL back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →